logo
Plus   Neg
Share
Email

Quest Diagnostics Affirms FY19 Outlook - Quick Facts

While reporting financial results for the second quarter, Quest Diagnostics Inc. (DGX) on Tuesday affirmed its full-year 2019 guidance for earnings to be greater than $5.29 per share and adjusted earnings to be greater than $6.40 per share on net revenues between $7.60 billion and $7.75 billion.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $6.46 per share on revenues of $7.69 billion for the year. Analysts' estimates typically exclude special items.

"We are excited by our new Preferred Lab Network status within UnitedHealthcare, which represents a multi-year opportunity that will build over time ," said Steve Rusckowski, Chairman, CEO and President.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Tuesday unveiled a new international collaboration for simultaneous review and approval of cancer drugs along with the agency's Australian and Canadian counterparts. The simultaneous approval of cancer therapies by the three regulators is intended to accelerate the process of making these new treatments available to patients around the world. Humanscale Corp. recalled about 24,900 units of QuickStand Lite workstations for concerns of injury hazard. These include about 2,200 units sold in Canada. The recalled workstation's arm can break and cause the workstation to fall, posing a risk of injury. The company has already received 52 reports of the arm breaking, including 12 reports of minor injuries. Facebook has revealed more details on the structure of an independent "oversight board" that will make final decisions about what posts stay up or come down, even if the company disagrees. The new "Oversight Board" will govern appeals from both Facebook and its users.
Follow RTT